Overview
Posttransplant acute limbic encephalitis (PALE) is a rare neurological complication that occurs following allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by acute inflammation of the limbic system — the brain structures involved in memory, emotion, and behavior, including the hippocampus, amygdala, and surrounding temporal lobe regions. The condition typically manifests within the first few months after transplantation and is believed to be related to immune-mediated mechanisms, potentially involving donor-derived immune cells reacting against the recipient's central nervous system, though the exact pathogenesis remains incompletely understood. Some cases have been associated with human herpesvirus 6 (HHV-6) reactivation. Key clinical features include acute onset of confusion, short-term memory loss, seizures (often temporal lobe epilepsy), disorientation, personality changes, and emotional disturbances. Brain MRI typically reveals characteristic signal abnormalities in the medial temporal lobes, particularly the hippocampi, on T2-weighted and FLAIR sequences. Cerebrospinal fluid analysis may show mild pleocytosis and elevated protein levels. The condition can progress rapidly and may lead to significant cognitive impairment if not promptly recognized and treated. Treatment approaches are largely empirical due to the rarity of the condition and include antiviral therapy (particularly when HHV-6 reactivation is suspected), immunosuppressive agents such as corticosteroids, and anticonvulsant medications for seizure management. Outcomes are variable; some patients may recover partially or fully, while others experience persistent neurological deficits, particularly memory impairment. Early recognition and intervention are considered important for improving prognosis. There are currently no standardized treatment guidelines, and management is typically individualized based on the suspected underlying etiology and clinical severity.
Also known as:
Clinical phenotype terms— hover any for plain English:
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Posttransplant acute limbic encephalitis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Posttransplant acute limbic encephalitis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Posttransplant acute limbic encephalitis.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Posttransplant acute limbic encephalitis.
Community
No community posts yet. Be the first to share your experience with Posttransplant acute limbic encephalitis.
Start the conversation →Latest news about Posttransplant acute limbic encephalitis
No recent news articles for Posttransplant acute limbic encephalitis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Posttransplant acute limbic encephalitis
What is Posttransplant acute limbic encephalitis?
Posttransplant acute limbic encephalitis (PALE) is a rare neurological complication that occurs following allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by acute inflammation of the limbic system — the brain structures involved in memory, emotion, and behavior, including the hippocampus, amygdala, and surrounding temporal lobe regions. The condition typically manifests within the first few months after transplantation and is believed to be related to immune-mediated mechanisms, potentially involving donor-derived immune cells reacting against the recipient's cen
At what age does Posttransplant acute limbic encephalitis typically begin?
Typical onset of Posttransplant acute limbic encephalitis is adult. Age of onset can vary across affected individuals.